- Price
- $27.15
- Day
- +6.01%
- Mkt Cap
- $4.65B
- 52W Range
- $19.69 – $28.35
- Volume
- 2.37M
- Beta
- 0.84
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript
Read full article
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another q.
Read full article
ACADIA Pharmaceuticals NASDAQ: ACAD reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and Parkinson's disease psychosis treatment NUPLAZID increased.
Read full article
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.16 per share a year ago.
Read full article
Avidity Partners Management LP cut its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 87.9% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,967 shares of the biopharmaceutical company's stock after selling 93,933 shares during the period. Avidity Partners Management LP's
Read full article
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time. Live webcasts will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is commit.
Read full article
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of these two stocks presents investors with the better value opportunity right now?
Read full article
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Acadia Pharmaceuticals Inc. ended July on a high note. The top line results from the Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis are expected in August-October 2026. Acadia expects its 2026 revenue will be $1.22-$1.28 billion, representing about 16.5% YoY growth.
Read full article
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
Read full article
The mean of analysts' price targets for Acadia (ACAD) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read full article
Bessemer Group Inc. lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 21,126.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,498 shares of the biopharmaceutical company's stock after buying an additional 149,789 shares during the period. Bessemer Group
Read full article